Home » Stocks » RTVA

Artiva Biotherapeutics, Inc. (RTVA)

Artiva Biotherapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -17.99M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Artiva Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

South Korea's pharmaceutical and biopharma companies are ramping up efforts to get listed on the Nasdaq market, hoping to follow in the footsteps of Korean e-commerce giant Coupang with their US market ...

1 month ago - The Korea Herald

About RTVA

Artiva Biotherapeutics' mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established manufacturing-first approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies. Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkin’s lymphoma (NHL). ... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Fred Aslan, M.D.
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
RTVA
Full Company Profile

Financial Performance

Financial Statements